FI770036A - - Google Patents

Info

Publication number
FI770036A
FI770036A FI770036A FI770036A FI770036A FI 770036 A FI770036 A FI 770036A FI 770036 A FI770036 A FI 770036A FI 770036 A FI770036 A FI 770036A FI 770036 A FI770036 A FI 770036A
Authority
FI
Finland
Application number
FI770036A
Other languages
Finnish (fi)
Inventor
Knut A Jaeggi
Franz Ostermayer
Herbert Schroeter
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI770036A publication Critical patent/FI770036A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/181,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/101,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FI770036A 1976-01-08 1977-01-06 FI770036A (US20080293856A1-20081127-C00150.png)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH16176A CH624395A5 (US20080293856A1-20081127-C00150.png) 1976-01-08 1976-01-08

Publications (1)

Publication Number Publication Date
FI770036A true FI770036A (US20080293856A1-20081127-C00150.png) 1977-07-09

Family

ID=4180641

Family Applications (1)

Application Number Title Priority Date Filing Date
FI770036A FI770036A (US20080293856A1-20081127-C00150.png) 1976-01-08 1977-01-06

Country Status (26)

Country Link
US (2) US4140789A (US20080293856A1-20081127-C00150.png)
JP (1) JPS5285166A (US20080293856A1-20081127-C00150.png)
AR (4) AR214869A1 (US20080293856A1-20081127-C00150.png)
AT (1) AT355564B (US20080293856A1-20081127-C00150.png)
AU (1) AU507884B2 (US20080293856A1-20081127-C00150.png)
BE (1) BE850166A (US20080293856A1-20081127-C00150.png)
CA (1) CA1083150A (US20080293856A1-20081127-C00150.png)
CH (1) CH624395A5 (US20080293856A1-20081127-C00150.png)
CS (1) CS201040B2 (US20080293856A1-20081127-C00150.png)
DD (1) DD129444A5 (US20080293856A1-20081127-C00150.png)
DE (1) DE2700193A1 (US20080293856A1-20081127-C00150.png)
DK (1) DK6177A (US20080293856A1-20081127-C00150.png)
ES (1) ES454779A1 (US20080293856A1-20081127-C00150.png)
FI (1) FI770036A (US20080293856A1-20081127-C00150.png)
FR (1) FR2337718A1 (US20080293856A1-20081127-C00150.png)
GB (1) GB1549945A (US20080293856A1-20081127-C00150.png)
GR (1) GR73132B (US20080293856A1-20081127-C00150.png)
IE (1) IE44246B1 (US20080293856A1-20081127-C00150.png)
IL (1) IL51222A (US20080293856A1-20081127-C00150.png)
NL (1) NL7700141A (US20080293856A1-20081127-C00150.png)
NO (1) NO770061L (US20080293856A1-20081127-C00150.png)
NZ (1) NZ182963A (US20080293856A1-20081127-C00150.png)
PL (4) PL110654B1 (US20080293856A1-20081127-C00150.png)
SE (1) SE7700056L (US20080293856A1-20081127-C00150.png)
SU (4) SU648091A3 (US20080293856A1-20081127-C00150.png)
ZA (1) ZA7787B (US20080293856A1-20081127-C00150.png)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624395A5 (US20080293856A1-20081127-C00150.png) * 1976-01-08 1981-07-31 Ciba Geigy Ag
DE2644833A1 (de) * 1976-10-05 1978-04-20 Boehringer Sohn Ingelheim Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung
NZ187066A (en) * 1977-05-03 1981-02-11 Hoffmann La Roche 4-(3-substitutedamino-2-hydroxypropoxy)-benzimidazolidin-2-(ones or thiones)
CA1108619A (en) * 1977-08-12 1981-09-08 Carl H. Ross 4-hydroxy-2-benzimidazolinone derivatives and the preparation thereof
DE2801980A1 (de) * 1978-01-18 1979-07-19 Boehringer Mannheim Gmbh 4-hydroxy-2-benzimidazolin-thion- derivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
EP0003758A1 (de) * 1978-02-09 1979-09-05 Ciba-Geigy Ag Verätherte Hydroxy-benzodiheterocyclen und ihre Säureadditionssalze, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE2905877A1 (de) * 1979-02-16 1980-08-28 Boehringer Mannheim Gmbh Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DD150456A5 (de) * 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
FR2455572B1 (fr) 1979-05-04 1986-07-25 Continental Pharma Derives de phenylethylamine, leur preparation et utilisation dans le traitement des affections cardiovasculaires, et compositions les contenant
DE2922084A1 (de) 1979-05-31 1980-12-11 Boehringer Mannheim Gmbh Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4442094A (en) * 1980-12-23 1984-04-10 Merck & Co., Inc. (3-Aralkylamino-2-or-propoxy)heterocyclic compounds
US4656168A (en) * 1980-12-23 1987-04-07 Merck & Co., Inc. (3-aralkylamino-2-or-propoxy)heterocyclic compounds in method of effecting bronchodilation
US4349673A (en) * 1980-12-23 1982-09-14 Merck & Co., Inc. Benzoxazines
US4331679A (en) * 1980-12-23 1982-05-25 Merck Sharp & Dohme (I.A.) Corp. (3-Aralkylamino-2-or-propoxy) heterocyclic compounds
DE3217012A1 (de) * 1982-05-06 1983-11-10 Dr. Karl Thomae Gmbh, 7950 Biberach Benzoxazin-2-one, deren herstellung und diese verbindungen enthaltende arzneimittel
IT1212552B (it) * 1982-10-20 1989-11-30 Italo Britannica L Manet Ti H Alcanolaminossi derivati di 3,4-diidro-2h-1.4-benzotiazin-3-one, loro procedimento di produzione e loro utilizzazione farmaceutica
GB8419797D0 (en) * 1984-08-03 1984-09-05 Beecham Group Plc Compounds
DE3800096A1 (de) * 1988-01-05 1989-07-13 Bayer Ag Verwendung von benzimidazolderivaten als leistungsfoerderer
FR2653430B1 (fr) * 1989-10-23 1991-12-20 Pf Medicament Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique.
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
US5972958A (en) * 1997-02-18 1999-10-26 American Home Products Corporation 4-aminoalkoxy-1,3-dihydro-benzoimidazol-2-thiones
US5922715A (en) * 1997-02-18 1999-07-13 American Home Products Corporation 5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
US5990144A (en) * 1997-02-18 1999-11-23 American Home Products Corporation 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one dopamine autoreceptor agonists
DE59804641D1 (de) 1997-09-24 2002-08-08 Infineon Technologies Ag o-Nitro(thio)phenolderivate und deren Herstellung
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
AU1580001A (en) * 1999-11-15 2001-05-30 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
FR2805159B1 (fr) 2000-02-23 2005-06-10 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n-(2-hydroxybenzene)-carbamate ou un n-(2-hydroxybenzene)-uree a titre de coupleur, et procedes de teinture
ATE329901T1 (de) 2000-11-10 2006-07-15 Lilly Co Eli 3-substituierte oxindolderivate als beta-3- agonisten
DE60215028T2 (de) 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
EP1444224B1 (en) 2001-08-14 2006-05-03 Eli Lilly And Company 3-substituted oxindole beta-3 agonists
ATE386740T1 (de) 2001-11-20 2008-03-15 Lilly Co Eli Beta-3 adrenergische agonisten
WO2003044016A1 (en) 2001-11-20 2003-05-30 Eli Lilly And Company 3-SUBSTITUTED OXINDOLE β3 AGONISTS
WO2003059348A1 (en) 2002-01-11 2003-07-24 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists
CA2496847C (en) * 2002-08-29 2011-06-07 Nissan Chemical Industries, Ltd. Process for producing aminobenzopyran compound
JP2007523873A (ja) * 2003-07-15 2007-08-23 スミスクライン・ビーチャム・コーポレイション 新規化合物
WO2008041118A2 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA726737A (en) * 1966-01-25 C. Scarborough Homer 4-substituted quinolines and quinazolines
US3686176A (en) * 1970-03-09 1972-08-22 Frosst & Co Charles E 1-morpholino phenoxy-3-alkylamino-2-propanols
US3763153A (en) * 1972-02-22 1973-10-02 Squibb & Sons Inc Benzothiazines
GB1488330A (en) * 1973-12-19 1977-10-12 Smith Kline French Lab Dihydropyridazinones
CH624395A5 (US20080293856A1-20081127-C00150.png) * 1976-01-08 1981-07-31 Ciba Geigy Ag

Also Published As

Publication number Publication date
PL112491B1 (en) 1980-10-31
IL51222A0 (en) 1977-03-31
ZA7787B (en) 1977-11-30
AT355564B (de) 1980-03-10
SU648092A3 (ru) 1979-02-15
US4140789A (en) 1979-02-20
AU507884B2 (en) 1980-02-28
PL112442B1 (en) 1980-10-31
US4310527A (en) 1982-01-12
SU651695A3 (ru) 1979-03-05
JPS5285166A (en) 1977-07-15
IL51222A (en) 1980-12-31
GR73132B (US20080293856A1-20081127-C00150.png) 1984-02-07
FR2337718B1 (US20080293856A1-20081127-C00150.png) 1980-11-07
DD129444A5 (de) 1978-01-18
IE44246B1 (en) 1981-09-23
SU645568A3 (ru) 1979-01-30
CA1083150A (en) 1980-08-05
CS201040B2 (en) 1980-10-31
PL112441B1 (en) 1980-10-31
AR215643A1 (es) 1979-10-31
IE44246L (en) 1977-07-08
SU648091A3 (ru) 1979-02-15
CH624395A5 (US20080293856A1-20081127-C00150.png) 1981-07-31
ATA4677A (de) 1979-08-15
AU2110577A (en) 1978-07-13
AR214869A1 (es) 1979-08-15
GB1549945A (en) 1979-08-08
DE2700193A1 (de) 1977-07-14
DK6177A (da) 1977-07-09
PL195154A1 (pl) 1979-05-07
SE7700056L (sv) 1977-07-09
FR2337718A1 (fr) 1977-08-05
NZ182963A (en) 1978-07-28
AR217258A1 (es) 1980-03-14
AR214746A1 (es) 1979-07-31
NL7700141A (nl) 1977-07-12
PL110654B1 (en) 1980-07-31
BE850166A (fr) 1977-07-07
ES454779A1 (es) 1978-01-01
NO770061L (no) 1977-07-11

Similar Documents

Publication Publication Date Title
FI770036A (US20080293856A1-20081127-C00150.png)
JPS52145157U (US20080293856A1-20081127-C00150.png)
JPS52143751U (US20080293856A1-20081127-C00150.png)
JPS52151071U (US20080293856A1-20081127-C00150.png)
CS178345B1 (US20080293856A1-20081127-C00150.png)
CS177789B1 (US20080293856A1-20081127-C00150.png)
CS177776B1 (US20080293856A1-20081127-C00150.png)
CH601779A5 (US20080293856A1-20081127-C00150.png)
CH607279A5 (US20080293856A1-20081127-C00150.png)
CH598597A5 (US20080293856A1-20081127-C00150.png)
CH598711A5 (US20080293856A1-20081127-C00150.png)
CH598778A5 (US20080293856A1-20081127-C00150.png)
CH598942A5 (US20080293856A1-20081127-C00150.png)
CH599204A5 (US20080293856A1-20081127-C00150.png)
CH599397A5 (US20080293856A1-20081127-C00150.png)
CH599403A5 (US20080293856A1-20081127-C00150.png)
CH599468A5 (US20080293856A1-20081127-C00150.png)
CH599494A5 (US20080293856A1-20081127-C00150.png)
CH599714A5 (US20080293856A1-20081127-C00150.png)
CH599870A5 (US20080293856A1-20081127-C00150.png)
CH600893A5 (US20080293856A1-20081127-C00150.png)
CH600995A5 (US20080293856A1-20081127-C00150.png)
CH601724A5 (US20080293856A1-20081127-C00150.png)
CH598213A5 (US20080293856A1-20081127-C00150.png)
CH598028A5 (US20080293856A1-20081127-C00150.png)

Legal Events

Date Code Title Description
FA Application withdrawn

Owner name: CIBA-GEIGY AG